A Multi-Stage Plasmodium vivax Malaria Vaccine Candidate Able to Induce Long-Lived Antibody Responses Against Blood Stage Parasites and Robust Transmission-Blocking Activity.

Frontiers in Cellular and Infection Microbiology
Jessica N McCafferyAlberto Moreno


Malaria control and interventions including long-lasting insecticide-treated nets, indoor residual spraying, and intermittent preventative treatment in pregnancy have resulted in a significant reduction in the number of Plasmodium falciparum cases. Considerable efforts have been devoted to P. falciparum vaccines development with much less to P. vivax. Transmission-blocking vaccines, which can elicit antibodies targeting Plasmodium antigens expressed during sexual stage development and interrupt transmission, offer an alternative strategy to achieve malaria control. The post-fertilization antigen P25 mediates several functions essential to ookinete survival but is poorly immunogenic in humans. Previous clinical trials targeting this antigen have suggested that conjugation to a carrier protein could improve the immunogenicity of P25. Here we report the production, and characterization of a vaccine candidate composed of a chimeric P. vivax Merozoite Surface Protein 1 (cPvMSP1) genetically fused to P. vivax P25 (Pvs25) designed to enhance CD4+ T cell responses and its assessment in a murine model. We demonstrate that antibodies elicited by immunization with this chimeric protein recognize both the erythrocytic and sexual stages and...Continue Reading


Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·H Zieler, J A Dvorak
Feb 27, 2001·Molecular and Biochemical Parasitology·D VlachouC Louis
Apr 5, 2001·Trends in Parasitology·T A SmithC Lengeler
Feb 14, 2002·International Journal for Parasitology·Romanico B G Arrighi, Hilary Hurd
Jun 18, 2002·Infection and Immunity·Ivette Caro-AguilarAlberto Moreno
Jun 10, 2004·Cellular Microbiology·Dina VlachouFotis C Kafatos
Nov 18, 2005·The American Journal of Tropical Medicine and Hygiene·Myriam Arévalo-HerreraSócrates Herrera
Dec 6, 2005·Nature Structural & Molecular Biology·Ajay K SaxenaDavid N Garboczi
Apr 10, 2007·Microbes and Infection·Robert W Sauerwein
May 18, 2007·Journal of Clinical Laboratory Analysis·C T PercianiM M Tanizaki
Jun 15, 2007·Eukaryotic Cell·Ajay K SaxenaDavid N Garboczi
Sep 1, 2007·Current Opinion in Infectious Diseases·Allan Saul
Jun 6, 2009·Tropical Medicine & International Health : TM & IH·Kamini MendisWalther H Wernsdorfer
Jul 31, 2009·The New England Journal of Medicine·Arjen M DondorpNicholas J White
Jul 31, 2009·The New England Journal of Medicine·Meta RoestenbergRobert Sauerwein
Aug 7, 2010·PLoS Neglected Tropical Diseases·Carlos A GuerraSimon I Hay
Sep 13, 2012·PLoS Neglected Tropical Diseases·Peter W GethingSimon I Hay
Dec 4, 2012·Advances in Parasitology·Katherine E BattleSimon I Hay
Nov 19, 2013·Lancet·Vasee S MoorthyJean-Marie Okwo-Bele
Oct 2, 2015·PLoS Pathogens·Thayer King, Tracey Lamb
Dec 24, 2015·Malaria Journal·Euzebiusz JamrozikMichael J Selgelid
Jun 30, 2016·PLoS Neglected Tropical Diseases·Andrés F VallejoMyriam Arévalo-Herrera
Nov 1, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicolas RiteauAlan Sher

❮ Previous
Next ❯

Methods Mentioned

gel filtration
flow cytometry

Software Mentioned

CTL ImmunoSpot
GraphPad Prism

Related Concepts

Related Feeds


Babesiosis is caused by parasites of the genus babesia, which are transmitted in nature by the bite of an infected tick. Discover the latest research on babesiosis here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.